Illuminating immunotherapy response via precision T cell-targeted PET imaging

被引:0
|
作者
Glazer, Sarah E. [1 ]
Kummar, Shivaani [2 ]
Mittra, Erik [3 ]
机构
[1] Oregon Hlth & Sci Univ, Div Internal Med, Portland, OR USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR USA
[3] Oregon Hlth & Sci Univ, Div Mol Imaging & Therapy, Portland, OR 97239 USA
关键词
PET; immunotherapy; radiopharmaceuticals; tumor immune microenvironment; predictive biomarkers; PREDICTIVE BIOMARKER; IN-VIVO; EXPRESSION; BLOCKADE; CANCER; INFILTRATION; ACTIVATION; ANTIBODY;
D O I
10.3389/fmed.2024.1233913
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Traditionally, immunotherapy agent selection and treatment strategies are guided by biopsy-based histological information. However, biopsies are limited in that they are invasive, provide static information regarding the tumor immune microenvironment, and only sample a small part of one tumor site. The tumor microenvironment is dynamic and heterogenous. As a result, the immune milieu at one site may be distinct from other metastatic sites. These factors make identifying which patients are likely to respond to different immunotherapies and which harbor intrinsic resistance mechanisms difficult to identify based on a biopsy alone. As such, there is significant interest in alternative methodologies that better characterize the tumor immune microenvironment and monitor immunotherapy response. PET imaging potentially offers a non-invasive way to characterize the tumor immune microenvironment at the primary tumor and metastases and allow for longitudinal characterization. Herein, we review pre-clinically and clinically tested T cell-targeted PET radiopharmaceuticals, as T cells have been the dominant immunotherapy target, and their utility in both evaluating response to immunotherapy and in understanding the systemic immune response to treatment with immunotherapeutics.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Natural Killer Cell-targeted Immunotherapy for Cancer
    Tang, Jingyi
    Zhu, Qi
    Li, Zhaoyang
    Yang, Jiahui
    Lai, Yu
    CURRENT STEM CELL RESEARCH & THERAPY, 2022, 17 (06) : 513 - 526
  • [2] Recent Advances in Cancer Stem Cell-Targeted Immunotherapy
    Badrinath, Narayanasamy
    Yoo, So Young
    CANCERS, 2019, 11 (03):
  • [3] Mathematical modelling of cancer stem cell-targeted immunotherapy
    Sigal, Daniel
    Przedborski, Michelle
    Sivaloganathan, Darshan
    Kohandel, Mohammad
    MATHEMATICAL BIOSCIENCES, 2019, 318
  • [4] T cell-targeted antibody reverses fibrosis
    Sarah Crunkhorn
    Nature Reviews Drug Discovery, 2016, 15 : 530 - 530
  • [5] Application of iNKT Cell-targeted Active Immunotherapy in Cancer Treatment
    Yamashita, Kimihiro
    Arimoto, Akira
    Nishi, Masayasu
    Tanaka, Tomoko
    Fujita, Mitsugu
    Fukuoka, Eiji
    Sugita, Yutaka
    Nakagawa, Akio
    Hasegawa, Hiroshi
    Suzuki, Satoshi
    Kakeji, Yoshihiro
    ANTICANCER RESEARCH, 2018, 38 (07) : 4233 - 4239
  • [6] Importance of regulatory T cell-targeted therapy
    Maeda, Yuka
    CANCER SCIENCE, 2024, 115 : 85 - 85
  • [7] Breaking Immunosuppression to Enhance Cancer Stem Cell-Targeted Immunotherapy
    Zheng, Fang
    Zhang, Shan
    Chang, Alfred E.
    Moon, James J.
    Wicha, Max S.
    Wang, Shelley Xuelai
    Chen, Junhui
    Liu, Jixian
    Cheng, Fanjun
    Li, Qiao
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2025, 21 (04): : 1819 - 1836
  • [8] The Dermis as a Portal for Dendritic Cell-Targeted Immunotherapy of Cutaneous Melanoma
    Oosterhoff, D.
    Sluijter, B. J. R.
    Hangalapura, B. N.
    de Gruijl, T. D.
    INTRADERMAL IMMUNIZATION, 2012, 351 : 181 - 220
  • [9] Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy
    Ou, Wenquan
    Thapa, Raj Kumar
    Jiang, Liyuan
    Soe, Zar Chi
    Gautam, Milan
    Chang, Jae-Hoon
    Jeong, Jee-Heon
    Ku, Sae Kwang
    Choi, Han-Gon
    Yong, Chul Soon
    Kim, Jong Oh
    JOURNAL OF CONTROLLED RELEASE, 2018, 281 : 84 - 96
  • [10] A novel regulatory T Cell-Targeted Immunotherapy by targeting their crucial signal by HSP90 inhibitors
    Tsuge, Ayaka
    Togashi, Yosuke
    Shitara, Kohei
    Nishikawa, Hiroyoshi
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7